TriangleAnti-CD19/CD20/CD22 CAR T-Cells (NCT05418088)
Anti-CD19/CD20/CD22 CAR T-Cells trial for Recurrent Acute Lymphoblastic Leukemia (NCT05418088). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells aimed at CD19 have rescued many people with relapsed B-cell leukemias and lymphomas. But the cancer adapts: drop CD19 from the surface, and the cells lose their target.
The idea: give the cancer three targets to lose instead of one.
At Ohio State and Nationwide Children's, a patient's T cells receive a single receptor that recognizes CD19, CD20, and CD22, three proteins found on B-cell cancers. After a short course of chemotherapy makes room, the cells go in as one infusion. Cohorts separate lower-burden disease from bulkier, faster leukemia and lymphoma, and the study includes children from age two.
An early safety and dose-finding trial. Sumithira Vasu leads it, with Margaret Lamb for pediatric patients. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.